- Datum16.12.2025
- Uhrzeit16:30 - 17:30 Uhr
- Veranstalter
stock3
Novo Nordisk AS Aktie
Verkaufen
Kaufen
Novo Nordisk AS Chart inkl. Chartanalyse
Charts analysieren
wie die Profis?
Nutze unser Profi-Charting-Tool für Deine eigenen Analysen
Chart analysieren
Novo Nordisk AS Realtime-Kurs
| Handelsplatz | Kurs | +/- (%) | +/- (abs) | Vortag | Zeit | Aktionen |
|---|---|---|---|---|---|---|
| L&S | VK | |||||
| Tradegate | VK | |||||
| Stuttgart | VK |
Passende Produkte
| WKN | Long/Short | KO | Hebel | Laufzeit | Bid | Ask |
|---|
Keine Ergebnisse gefunden
Wertentwicklung (XETRA)
0,44 %
Intraday
3,96 %
1 Woche
1,22 %
1 Monat
-48,55 %
Seit Jahresbeginn
-57,16 %
1 Jahr
-31,25 %
3 Jahre
50,50 %
5 Jahre
68,35 %
10 Jahre
Passender Service zu Novo Nordisk AS
Webinar zu Novo Nordisk AS
Kursinformationen (XETRA)
- Tagestief / Hoch (€)-
- 52W-Tief / Hoch (€)35,755-104,780
- Jahrestief / Hoch (€)---
- Schlusskurs (Vortag)
- Eröffnungskurs
- Volumen Intraday
Wichtigste Eigenschaften
Dividenden von Novo Nordisk AS
| Ex-Datum | Fiskaljahr | Dividende | Rendite |
|---|---|---|---|
| - | 2028 (e) | ||
| - | 2027 (e) | ||
| - | 2026 (e) | ||
| 15.08.2025 | 2025 | 3,75 kr | 1,15 % |
| - | 2025 (e) | ||
| 15.08.2024 | 2024 | 3,50 kr | 0,38 % |
| 28.03.2025 | 2024 | 7,90 kr | 1,62 % |
| 22.03.2024 | 2023 | 6,40 kr | 0,71 % |
Termine von Novo Nordisk AS
- Feb4Novo Nordisk ASQ4 2025 Earnings Release
- Apr30Novo Nordisk ASQ1 2026 Earnings Release
- Aug6Novo Nordisk ASQ2 2026 Earnings Release
Beschreibung
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Rare Disease. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, glucagon, needles, and other chronic diseases. The Rare Disease segment offers products in the areas of haemophilia, blood disorders, endocrine disorders, growth disorders, and hormone replacement therapy. The company has a collaboration agreement with Gilead Sciences, Inc.; and research collaboration with Novo Nordisk to discover cell-specific carriers of nucleic acid therapeutics. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
